Home
Resources
Publications
Novel MAO-B Inhibitors: Potential Therapeutic Use of the Selective MAO-B Inhibitor PF9601N in Parkinson's Disease

Novel MAO-B Inhibitors: Potential Therapeutic Use of the Selective MAO-B Inhibitor PF9601N in Parkinson's Disease

Mercedes Unzeta, Elisenda Sanz

Int Rev Neurobiol. 2011;100:217-36.

PMID: 21971010

Abstract:

Parkinson's disease (PD) is a neurodegenerative disease that is characterized by preferential loss of dopaminergic neurons in the substantia nigra pars compacta, leading to declining levels of dopamine in the striatum. In our search for compounds able not only to extend the effects of dopamine by preventing its degradation but also to halt or slow the neurodegenerative process, we designed, synthesized, and biologically tested a series of propargylamines for their potential use as therapeutic agents for PD. Among them, PF9601N, [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine], showed high potency and selectivity as a MAO-BI (monoamine oxidase type B inhibitor) and also demonstrated remarkable neuroprotective properties in several in vivo and cellular models of PD. In this chapter, we describe the preclinical evidence revealing the novel MAO-BI PF9601N as an interesting candidate for the treatment of PD.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP133845633	PF9601N		133845-63-3	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: